John J V McMurray

Summary

Country: UK

Publications

  1. doi request reprint ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart
    John J V McMurray
    Glasgow G12 8QQ, UK
    Eur J Heart Fail 14:803-69. 2012
  2. pmc Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact
    John J V McMurray
    BHF Cardiovascular Research Centre, University of Glasgow, UK
    Eur J Heart Fail 15:1062-73. 2013
  3. doi request reprint Left ventricular systolic dysfunction, heart failure, and the risk of stroke and systemic embolism in patients with atrial fibrillation: insights from the ARISTOTLE trial
    John J V McMurray
    BHF Cardiovascular Research Centre, University of Glasgow, Glasgow, Scotland, United Kingdom
    Circ Heart Fail 6:451-60. 2013
  4. doi request reprint Eplerenone in patients with systolic heart failure and mild symptoms: analysis of repeat hospitalizations
    Jennifer K Rogers
    London School of Hygiene and Tropical Medicine, London, United Kingdom
    Circulation 126:2317-23. 2012
  5. doi request reprint Heart failure in 2011: Heart failure therapy--technology to the fore
    John J V McMurray
    British Heart Foundation Cardiovascular Research Centre, University of Glasgow, 126 University Place, Glasgow G12 8TA, UK
    Nat Rev Cardiol 9:73-4. 2012
  6. doi request reprint Predictors of fatal and nonfatal cardiovascular events in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia: an analysis of the Trial to Reduce cardiovascular Events with Aranesp (darbepoetin-alfa) Therapy (TREAT)
    John J V McMurray
    BHF Glasgow Cardiovascular Research Centre, University of Glasgow, United Kingdom
    Am Heart J 162:748-755.e3. 2011
  7. doi request reprint Coenzyme Q10, rosuvastatin, and clinical outcomes in heart failure: a pre-specified substudy of CORONA (controlled rosuvastatin multinational study in heart failure)
    John J V McMurray
    BHF Glasgow Cardiovascular Research Centre, University of Glasgow, 126 University Place, Glasgow, United Kingdom
    J Am Coll Cardiol 56:1196-204. 2010
  8. doi request reprint CONSENSUS to EMPHASIS: the overwhelming evidence which makes blockade of the renin-angiotensin-aldosterone system the cornerstone of therapy for systolic heart failure
    John J V McMurray
    BHF Glasgow Cardiovascular Research Centre, University of Glasgow, G12 8TA UK
    Eur J Heart Fail 13:929-36. 2011
  9. doi request reprint Albuminuria in chronic heart failure: prevalence and prognostic importance
    Colette E Jackson
    British Heart Foundation Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, UK
    Lancet 374:543-50. 2009
  10. doi request reprint Microvascular obstruction remains a portent of adverse remodeling in optimally treated patients with left ventricular systolic dysfunction after acute myocardial infarction
    Robin A P Weir
    Cardiology Department, Western Infirmary, Glasgow, Scotland, United Kingdom
    Circ Cardiovasc Imaging 3:360-7. 2010

Detail Information

Publications87

  1. doi request reprint ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart
    John J V McMurray
    Glasgow G12 8QQ, UK
    Eur J Heart Fail 14:803-69. 2012
  2. pmc Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact
    John J V McMurray
    BHF Cardiovascular Research Centre, University of Glasgow, UK
    Eur J Heart Fail 15:1062-73. 2013
    ..LCZ696 belongs to a new class of drugs, the angiotensin receptor neprilysin inhibitors (ARNIs), which both block the RAAS and augment natriuretic peptides...
  3. doi request reprint Left ventricular systolic dysfunction, heart failure, and the risk of stroke and systemic embolism in patients with atrial fibrillation: insights from the ARISTOTLE trial
    John J V McMurray
    BHF Cardiovascular Research Centre, University of Glasgow, Glasgow, Scotland, United Kingdom
    Circ Heart Fail 6:451-60. 2013
    ....
  4. doi request reprint Eplerenone in patients with systolic heart failure and mild symptoms: analysis of repeat hospitalizations
    Jennifer K Rogers
    London School of Hygiene and Tropical Medicine, London, United Kingdom
    Circulation 126:2317-23. 2012
    ..In chronic diseases such as heart failure, characterized by repeat hospitalizations, analyzing all heart failure hospitalizations, not just the first, should give a more complete picture of treatment benefits...
  5. doi request reprint Heart failure in 2011: Heart failure therapy--technology to the fore
    John J V McMurray
    British Heart Foundation Cardiovascular Research Centre, University of Glasgow, 126 University Place, Glasgow G12 8TA, UK
    Nat Rev Cardiol 9:73-4. 2012
    ..Conversely, the efficacy of nesiritide in acute heart failure has been questioned...
  6. doi request reprint Predictors of fatal and nonfatal cardiovascular events in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia: an analysis of the Trial to Reduce cardiovascular Events with Aranesp (darbepoetin-alfa) Therapy (TREAT)
    John J V McMurray
    BHF Glasgow Cardiovascular Research Centre, University of Glasgow, United Kingdom
    Am Heart J 162:748-755.e3. 2011
    ..Individuals with the triad of diabetes, CKD, and anemia represent a significant proportion of patients with cardiovascular disease and are at particularly high risk for adverse outcomes...
  7. doi request reprint Coenzyme Q10, rosuvastatin, and clinical outcomes in heart failure: a pre-specified substudy of CORONA (controlled rosuvastatin multinational study in heart failure)
    John J V McMurray
    BHF Glasgow Cardiovascular Research Centre, University of Glasgow, 126 University Place, Glasgow, United Kingdom
    J Am Coll Cardiol 56:1196-204. 2010
    ..The purpose of this study was to determine whether coenzyme Q₁₀ is an independent predictor of prognosis in heart failure...
  8. doi request reprint CONSENSUS to EMPHASIS: the overwhelming evidence which makes blockade of the renin-angiotensin-aldosterone system the cornerstone of therapy for systolic heart failure
    John J V McMurray
    BHF Glasgow Cardiovascular Research Centre, University of Glasgow, G12 8TA UK
    Eur J Heart Fail 13:929-36. 2011
    ..In this article I will give a brief, historical overview of this exciting quarter-century of discovery related to the RAAS. My focus is on the treatment of heart failure in patients with a low left ventricular ejection fraction...
  9. doi request reprint Albuminuria in chronic heart failure: prevalence and prognostic importance
    Colette E Jackson
    British Heart Foundation Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, UK
    Lancet 374:543-50. 2009
    ..Therefore our aim was to assess the prevalence and prognostic value of a spot urinary albumin to creatinine ratio (UACR) in patients with heart failure...
  10. doi request reprint Microvascular obstruction remains a portent of adverse remodeling in optimally treated patients with left ventricular systolic dysfunction after acute myocardial infarction
    Robin A P Weir
    Cardiology Department, Western Infirmary, Glasgow, Scotland, United Kingdom
    Circ Cardiovasc Imaging 3:360-7. 2010
    ..We examined the influence of several infarct characteristics, including MO, on LV remodeling in an optimally treated post-acute myocardial infarction cohort, using contrast-enhanced cardiac magnetic resonance...
  11. ncbi request reprint Prevalence and prognostic impact of bundle branch block in patients with heart failure: evidence from the CHARM programme
    Nathaniel M Hawkins
    Stobhill Hospital, Glasgow, UK
    Eur J Heart Fail 9:510-7. 2007
    ..The prognostic implications in HF with preserved systolic function (HF-PSF) are less well understood...
  12. doi request reprint Interleukin-21--a biomarker of importance in predicting myocardial function following acute infarction?
    Robin A P Weir
    Cardiology Department, Hairmyres Hospital, Lanarkshire, Scotland, UK
    Cytokine 60:220-5. 2012
    ..Interleukin-21 (IL-21) plays a key role in immunoregulation; whether IL-21 is associated with left ventricular (LV) remodelling after AMI is unknown...
  13. doi request reprint Efficacy and tolerability of adding an angiotensin receptor blocker in patients with heart failure already receiving an angiotensin-converting inhibitor plus aldosterone antagonist, with or without a beta blocker. Findings from the Candesartan in Heart fa
    R A P Weir
    Department of Cardiology, Western Infirmary, Glasgow, G11 6NT, United Kingdom Faculty of Medicine, University of Glasgow, United Kingdom
    Eur J Heart Fail 10:157-63. 2008
    ..The CHARM-Added trial describes the largest experience of using multiple inhibitors of the renin-angiotensin-aldosterone system (RAAS) together...
  14. doi request reprint Long-term trends in first hospitalization for heart failure and subsequent survival between 1986 and 2003: a population study of 5.1 million people
    Pardeep S Jhund
    BHF Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, G12 8TA, United Kingdom
    Circulation 119:515-23. 2009
    ..We also examined trends in the prescribing of evidence-based pharmacological treatment for HF...
  15. doi request reprint Clinical outcomes according to baseline blood pressure in patients with a low ejection fraction in the CHARM (Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity) Program
    Peter A Meredith
    Faculty of Medicine, University of Glasgow, Glasgow, Scotland
    J Am Coll Cardiol 52:2000-7. 2008
    ..40) in the CHARM (Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity) program...
  16. doi request reprint Age- and sex-specific trends in fatal incidence and hospitalized incidence of stroke in Scotland, 1986 to 2005
    James D Lewsey
    Department of Public Health, British Heart Foundation, Glasgow Cardiovascular Research Centre, University of Glasgow, United Kingdom
    Circ Cardiovasc Qual Outcomes 2:475-83. 2009
    ..Temporal trends in stroke incidence are unclear. We aimed to examine age- and sex-specific temporal trends in incidence of fatal and nonfatal hospitalized stroke in Scotland from 1986 to 2005...
  17. doi request reprint Clinical characteristics and outcomes of young and very young adults with heart failure: The CHARM programme (Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity)
    Chih M Wong
    BHF Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, United Kingdom Scottish National Advanced Heart Failure Service, Golden Jubilee National Hospital, Clydebank, Glasgow, United Kingdom
    J Am Coll Cardiol 62:1845-54. 2013
    ..This study sought to determine the characteristics and outcomes of young adults with heart failure (HF)...
  18. ncbi request reprint Sex differences in clinical characteristics and prognosis in a broad spectrum of patients with heart failure: results of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program
    Tim Clayton
    Western Infirmary, Glasgow, Scotland, UK
    Circulation 115:3111-20. 2007
    ....
  19. pmc Baseline characteristics of patients in the Reduction of Events with Darbepoetin alfa in Heart Failure trial (RED-HF)
    John J V McMurray
    Institute of Cardiovascular and Medical Sciences, BHF Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow G12 8TA, UK
    Eur J Heart Fail 15:334-41. 2013
    ....
  20. ncbi request reprint Relationship of dose of background angiotensin-converting enzyme inhibitor to the benefits of candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Added trial
    John J V McMurray
    Department of Cardiology, Western Infirmary, Glasgow, Scotland
    Am Heart J 151:985-91. 2006
    ..Whether an angiotensin receptor blocker is of benefit when added to a full dose of angiotensin-converting enzyme (ACE) inhibitor in heart failure (HF) is uncertain...
  21. doi request reprint Estimating the impact of stroke unit care in a whole population: an epidemiological study using routine data
    Peter Langhorne
    Cardiovascular and Medical Sciences Division, University of Glasgow, Glasgow, UK
    J Neurol Neurosurg Psychiatry 81:1301-5. 2010
    ..However, it is unclear what impact this complex intervention actually has in routine practice. A comprehensive national dataset was used to study the impact of stroke unit implementation...
  22. doi request reprint Monocyte chemoattractant protein-1: a dichotomous role in cardiac remodeling following acute myocardial infarction in man?
    Robin A P Weir
    Cardiology Department, Western Infirmary, Glasgow, Scotland, UK
    Cytokine 50:158-62. 2010
    ..We examined the relationships between serum MCP-1, change in LV function and biomarkers related to remodeling in a cohort of AMI patients...
  23. doi request reprint Associations of albuminuria in patients with chronic heart failure: findings in the ALiskiren Observation of heart Failure Treatment study
    Colette E Jackson
    British Heart Foundation Cardiovascular Research Centre, University of Glasgow, 126 University Place, Glasgow, UK
    Eur J Heart Fail 13:746-54. 2011
    ..To examine the relationships between baseline characteristics and urinary albumin excretion in the extensively phenotyped patients in the ALiskiren Observation of heart Failure Treatment (ALOFT) study...
  24. doi request reprint Aldosterone and cortisol predict medium-term left ventricular remodelling following myocardial infarction
    Robin A P Weir
    Cardiology Department, Western Infirmary, Glasgow, UK
    Eur J Heart Fail 13:1305-13. 2011
    ..We examined the relationships between plasma and urinary steroid hormones and left ventricular (LV) remodelling in patients with LV dysfunction following AMI...
  25. doi request reprint Serum soluble ST2: a potential novel mediator in left ventricular and infarct remodeling after acute myocardial infarction
    Robin A P Weir
    Cardiology Department, Western Infirmary, Glasgow, Scotland, United Kingdom
    J Am Coll Cardiol 55:243-50. 2010
    ....
  26. ncbi request reprint Clinical correlates and consequences of anemia in a broad spectrum of patients with heart failure: results of the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) Program
    Eileen O'Meara
    Western Infirmary, Glasgow, UK
    Circulation 113:986-94. 2006
    ..We wished to determine the prevalence of, potential mechanistic associations of, and clinical outcomes related to anemia in patients with heart failure and a broad spectrum of left ventricular ejection fraction (LVEF)...
  27. doi request reprint Left ventricular remodeling after acute myocardial infarction: does eplerenone have an effect?
    Robin A P Weir
    Cardiology Department, Western Infirmary, Glasgow, Scotland, United Kingdom
    Am Heart J 157:1088-96. 2009
    ..The mechanism of this effect is unclear. We performed a contrast-enhanced cardiac magnetic resonance study to assess the effects of eplerenone on LV remodeling after AMI...
  28. pmc Treatment of type 2 diabetes and outcomes in patients with heart failure: a nested case-control study from the U.K. General Practice Research Database
    Michael R MacDonald
    Golden Jubilee National Hospital, Glasgow, Scotland
    Diabetes Care 33:1213-8. 2010
    ..We designed this study to determine whether this association reflects a beneficial effect of metformin or a harmful effect of other agents...
  29. pmc A national survey of the prevalence, incidence, primary care burden and treatment of atrial fibrillation in Scotland
    Niamh F Murphy
    Department of Cardiology, Western Infirmary, Glasgow, UK
    Heart 93:606-12. 2007
    ..To examine the epidemiology, primary care burden and treatment of atrial fibrillation (AF)...
  30. pmc Trends in incidence and in short term survival following a subarachnoid haemorrhage in Scotland, 1986-2005: a retrospective cohort study
    Karen J Macpherson
    NHS Quality Improvement Scotland, Glasgow, UK
    BMC Neurol 11:38. 2011
    ..To examine age and sex specific incidence and 30 day case fatality for subarachnoid haemorrhage (SAH) in Scotland over a 20 year period...
  31. pmc An economic evaluation of rosuvastatin treatment in systolic heart failure: evidence from the CORONA trial
    Paula K Lorgelly
    Section of Public Health and Health Policy, Faculty of Medicine, University of Glasgow, Glasgow G12 8RZ, UK
    Eur J Heart Fail 12:66-74. 2010
    ..To estimate the cost-effectiveness of 10 mg rosuvastatin daily for older patients with systolic heart failure in the Controlled Rosuvastatin Multinational Study in Heart Failure (CORONA) trial...
  32. doi request reprint Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme
    Michael R MacDonald
    Glasgow Royal Infirmary, Glasgow, UK
    Eur Heart J 29:1377-85. 2008
    ..To determine whether the risk of adverse cardiovascular (CV) outcomes associated with diabetes differs in patients with low and preserved ejection fraction (EF) heart failure (HF)...
  33. pmc Predictors of development of diabetes in patients with chronic heart failure in the Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM) program
    David Preiss
    BHF Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, Scotland, UK
    Diabetes Care 32:915-20. 2009
    ....
  34. doi request reprint Effects of statin therapy according to plasma high-sensitivity C-reactive protein concentration in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): a retrospective analysis
    John J V McMurray
    British Heart Foundation Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, G12 8TA, UK
    Circulation 120:2188-96. 2009
    ..We examined whether the antiinflammatory action of statins may be of benefit in heart failure, a state characterized by inflammation in which low cholesterol is associated with worse outcomes...
  35. doi request reprint Intermittent claudication as a predictor of outcome in patients with ischaemic systolic heart failure: analysis of the Controlled Rosuvastatin Multinational Trial in Heart Failure trial (CORONA)
    Sally C Inglis
    BHF Glasgow Cardiovascular Research Centre, University of Glasgow, 126 University Place, Glasgow G12 8TA, UK
    Eur J Heart Fail 12:698-705. 2010
    ..Patients aged >or=60 years with NYHA class II-IV, low ejection fraction HF of ischaemic aetiology were enrolled in CORONA. Rosuvastatin did not reduce the primary outcome or all-cause mortality...
  36. doi request reprint Plasma apelin concentration is depressed following acute myocardial infarction in man
    Robin A P Weir
    Cardiology Department, Western Infirmary, Glasgow G11 6NT, Scotland, UK
    Eur J Heart Fail 11:551-8. 2009
    ..We aimed to characterize plasma apelin concentrations following AMI and to examine its relationship with clinical and prognostic biomarkers...
  37. doi request reprint What have we learned about patients with heart failure and preserved ejection fraction from DIG-PEF, CHARM-preserved, and I-PRESERVE?
    Ross T Campbell
    University of Glasgow, Glasgow, United Kingdom
    J Am Coll Cardiol 60:2349-56. 2012
    ....
  38. doi request reprint Eplerenone and new-onset diabetes in patients with mild heart failure: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF)
    David Preiss
    British Heart Foundation Cardiovascular Research Centre, University of Glasgow, Glasgow G12 8TA, UK
    Eur J Heart Fail 14:909-15. 2012
    ..In addition, though the combination of diabetes and chronic heart failure (CHF) carries a poor prognosis, few studies have examined predictors of new-onset diabetes in those with CHF...
  39. doi request reprint Discordant short- and long-term outcomes associated with diabetes in patients with heart failure: importance of age and sex: a population study of 5.1 million people in Scotland
    Michael R MacDonald
    Advanced Heart Failure Service, Golden Jubilee National Hospital, Glasgow, United Kingdom
    Circ Heart Fail 1:234-41. 2008
    ..Our aim was to assess the association between diabetes and short- and long-term outcomes in all patients admitted to the hospital for the first time with heart failure in Scotland between 1986 and 2003...
  40. pmc Temporal trends in hospitalisation for stroke recurrence following incident hospitalisation for stroke in Scotland
    James Lewsey
    Public Health and Health Policy, University of Glasgow, Glasgow, UK
    BMC Med 8:23. 2010
    ..The aim of this study was to examine temporal trends in hospitalisation for stroke recurrence following incident hospitalisation for stroke in Scotland during 1986 to 2001...
  41. doi request reprint Diabetes, left ventricular systolic dysfunction, and chronic heart failure
    Michael R MacDonald
    Glasgow Royal Infirmary, Glasgow, UK
    Eur Heart J 29:1224-40. 2008
    ..This article forms a comprehensive overview of a fascinating intersection between two common diseases...
  42. doi request reprint Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure
    John J V McMurray
    BHF Cardiovascular Research Centre, University of Glasgow, Glasgow, Scotland, United Kingdom
    Circ Heart Fail 1:17-24. 2008
    ..This may overcome ACE inhibition but should be blocked by a direct renin inhibitor. We studied the effects of adding the direct renin inhibitor aliskiren to an ACE inhibitor in patients with heart failure...
  43. ncbi request reprint Which inhibitor of the renin-angiotensin system should be used in chronic heart failure and acute myocardial infarction?
    John J V McMurray
    Department of Cardiology, Western Infirmary, Glasgow, Scotland, G12 8QQ, UK
    Circulation 110:3281-8. 2004
  44. doi request reprint Plasma TIMP-4 predicts left ventricular remodeling after acute myocardial infarction
    Robin A P Weir
    Cardiology Department, Western Infirmary, Glasgow, Scotland, UK
    J Card Fail 17:465-71. 2011
    ..No relationships have been identified between TIMPs and serial postinfarction change in LV function...
  45. doi request reprint Spectral microvolt T-wave alternans testing has no prognostic value in patients recently hospitalized with decompensated heart failure
    Colette E Jackson
    British Heart Foundation Cardiovascular Research Centre, University of Glasgow, Glasgow, UK
    Eur J Heart Fail 15:1253-61. 2013
    ..The aim of this study was to determine the prevalence and incremental prognostic value of spectral MTWA testing in an unselected cohort of patients recently hospitalized with HF...
  46. doi request reprint Profile of microvolt T-wave alternans testing in 1003 patients hospitalized with heart failure
    Colette E Jackson
    British Heart Foundation Cardiovascular Research Centre, University of Glasgow, 126 University Place, Glasgow, UK
    Eur J Heart Fail 14:377-86. 2012
    ..The aims of this study were to investigate the utility of MTWA testing in an unselected population of patients with HF and to evaluate the clinical characteristics associated with the MTWA results...
  47. doi request reprint Design of the Reduction of Events with Darbepoetin alfa in Heart Failure (RED-HF): a Phase III, anaemia correction, morbidity-mortality trial
    John J V McMurray
    British Heart Foundation Cardiovascular Research Centre, University of Glasgow, Glasgow, UK
    Eur J Heart Fail 11:795-801. 2009
    ..Whether correcting anaemia can improve outcomes is unknown...
  48. doi request reprint Potentially detrimental cardiovascular effects of oxygen in patients with chronic left ventricular systolic dysfunction
    James H Park
    British Heart Foundation Cardiovascular Research Centre, University of Glasgow, 126 University Place, Glasgow, UK
    Heart 96:533-8. 2010
    ..Although the haemodynamic effects of oxygen in healthy subjects are well documented, there have been no well-controlled studies of the effects of oxygen in patients with heart failure (HF)...
  49. ncbi request reprint Resource utilization and costs in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme
    John J V McMurray
    Department of Cardiology, Level 4, Western Infirmary, Glasgow, Scotland, UK
    Eur Heart J 27:1447-58. 2006
    ..We have carried out a prospective economic analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme...
  50. doi request reprint Sex differences in incidence, mortality, and survival in individuals with stroke in Scotland, 1986 to 2005
    James D Lewsey
    Public Health and Health Policy, University of Glasgow, Glasgow, UK
    Stroke 40:1038-43. 2009
    ..The aim of this study was to examine the effect of sex across different age groups and over time for stroke incidence, 30-day case-fatality, and mortality...
  51. doi request reprint How small is too small? A systematic review of center volume and outcome after cardiac transplantation
    Stephen J Pettit
    Scottish National Advanced Heart Failure Service, Golden Jubilee National Hospital, Clydebank, Glasgow, United Kingdom
    Circ Cardiovasc Qual Outcomes 5:783-90. 2012
    ..The aim of this study was to assess the relationship between the volume of cardiac transplantation procedures performed in a center and the outcome after cardiac transplantation...
  52. doi request reprint Patients with prior coronary artery bypass grafting have a poor outcome after myocardial infarction: an analysis of the VALsartan in acute myocardial iNfarcTion trial (VALIANT)
    Colin Berry
    Faculty of Medicine, BHF Cardiovascular Research Centre, University of Glasgow, Glasgow, Scotland, UK
    Eur Heart J 30:1450-6. 2009
    ..We compared the baseline characteristics, treatment, and clinical outcomes of patients with and without prior CABG in the VALIANT trial...
  53. ncbi request reprint Val-HeFT: do angiotensin-receptor blockers benefit heart failure patients already receiving ACE inhibitor therapy?
    John J V McMurray
    University of Glasgow, Scotland
    Nat Clin Pract Cardiovasc Med 2:128-9. 2005
  54. doi request reprint Cardiac and extracardiac abnormalities detected by cardiac magnetic resonance in a post-myocardial infarction cohort
    Robin A P Weir
    Cardiology Department, Western Infirmary, Glasgow, UK
    Cardiology 113:1-8. 2009
    ..This study sought to determine the impact of contrast-enhanced CMR (ceCMR) scanning before discharge in addition to standard transthoracic echocardiography (TTE) on patient care following AMI...
  55. ncbi request reprint Pharmacologic management of patients with both heart failure and diabetes
    Michael R MacDonald
    Department of Cardiology, Hairmyres Hospital, Eaglesham Road, East Kilbride, Glasgow G75 8RG, Scotland, United Kingdom
    Curr Heart Fail Rep 6:126-32. 2009
    ..This article aims to clarify the evidence behind treating these conditions simultaneously and dispel the myths surrounding the pharmacologic management of diabetes in heart failure and vice versa...
  56. pmc Incidence and prevalence of unrecognized myocardial infarction in people with diabetes: a substudy of the Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycemia in Diabetes (RECORD) study
    Michael R MacDonald
    Golden Jubilee National Hospital, Glasgow, UK
    Diabetes Care 34:1394-6. 2011
    ..To examine the prevalence and incidence of unrecognized myocardial infarction in a contemporary population with type 2 diabetes...
  57. doi request reprint Radiofrequency ablation for persistent atrial fibrillation in patients with advanced heart failure and severe left ventricular systolic dysfunction: a randomised controlled trial
    Michael R MacDonald
    Golden Jubilee NationalHospital, Glasgow, Scotland, UK
    Heart 97:740-7. 2011
    ..Objective: To determine whether or not radiofrequency ablation (RFA) for persistent atrial fibrillation in patients with advanced heart failure leads to improvements in cardiac function...
  58. doi request reprint Effect of aliskiren in patients with heart failure according to background dose of ACE inhibitor: a retrospective analysis of the Aliskiren Observation of Heart Failure Treatment (ALOFT) trial
    Novalia P Sidik
    British Heart Foundation Cardiovascular Research Centre, University of Glasgow, 126 University Place, Glasgow, G12 8TA, UK
    Cardiovasc Drugs Ther 25:315-21. 2011
    ..To compare the effect of the direct renin inhibitor aliskiren on neurohumoral activity in heart failure patients treated with low-dose and high-dose ACE inhibitor...
  59. doi request reprint Thyroid-Stimulating Hormone and Clinical Outcomes: The CORONA Trial (Controlled Rosuvastatin Multinational Study in Heart Failure)
    Ana Cristina Perez
    BHF Cardiovascular Research Centre, University of Glasgow, Glasgow, Scotland
    JACC Heart Fail 2:35-40. 2014
    ..This study sought to examine the association between thyroid status and clinical outcomes in patients in the CORONA (Controlled Rosuvastatin Multinational Trial in Heart Failure) study...
  60. doi request reprint Predictors of stroke in patients with impaired glucose tolerance: results from the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research trial
    David Preiss
    University of Glasgow, Glasgow, UK
    Stroke 44:2590-3. 2013
    ..Risk factors for stroke are well-established in general populations but sparsely studied in individuals with impaired glucose tolerance...
  61. doi request reprint Angina and intermittent claudication in 7403 participants of the 2003 Scottish Health Survey: impact on general and mental health, quality of life and five-year mortality
    Sally C Inglis
    BHF Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, United Kingdom
    Int J Cardiol 167:2149-55. 2013
    ..Both symptoms have similar etiology, yet the physical and psychological impacts of these symptoms are rarely studied in community-based cohorts or in individuals with isolated symptoms...
  62. doi request reprint Peripheral artery disease and outcomes after myocardial infarction: an individual-patient meta-analysis of 28,771 patients in CAPRICORN, EPEHESUS, OPTIMAAL and VALIANT
    Sally C Inglis
    BHF Glasgow Cardiovascular Research Centre, University of Glasgow, UK Preventative Health, Baker IDI Heart and Diabetes Institute, Melbourne, Australia Faculty of Nursing, Midwifery and Health, University of Technology, Sydney, Sydney Australia
    Int J Cardiol 168:1094-101. 2013
    ....
  63. ncbi request reprint Ximelagatran compared with warfarin for the prevention of systemic embolism and stroke. An imputed placebo analysis
    Colin Berry
    Department of Cardiology, Western Infirmary, Glasgow, Scotland, UK
    Cardiovasc Drugs Ther 19:149-51. 2005
    ..Based on these data, ximelagatran may be an effective alternative to warfarin for the prevention of stroke and systemic embolism in high-risk patients with atrial fibrillation...
  64. ncbi request reprint The prevalence, nature, and importance of hematologic abnormalities in heart failure
    Colin Berry
    Department of Cardiology, Western Infirmary, Glasgow, Scotland
    Am Heart J 151:1313-21. 2006
    ..Anemia is an adverse prognostic marker in heart failure (HF), but its cause and relationships with other comorbidities are uncertain...
  65. ncbi request reprint Epidemiology of heart failure and left ventricular dysfunction after acute myocardial infarction
    Robin A P Weir
    Department of Cardiology, Western Infirmary, Glasgow, G11 6NT, United Kingdom
    Curr Heart Fail Rep 3:175-80. 2006
    ..Advances in the management of acute myocardial infarction have led to reduced in-hospital mortality (even when complicated by heart failure), but longer-term mortality remains high in these patients...
  66. ncbi request reprint Is microvolt T-wave alternans the answer to risk stratification in heart failure?
    Rachel C Myles
    British Heart Foundation Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, UK
    Circulation 116:2984-91. 2007
  67. ncbi request reprint The year in heart failure
    John J V McMurray
    Department of Cardiology, Western Infirmary, Glasgow G12 8QQ, Scotland, UK
    J Am Coll Cardiol 44:2398-405. 2004
  68. ncbi request reprint A randomized, placebo-controlled trial assessing the effects of rosiglitazone on echocardiographic function and cardiac status in type 2 diabetic patients with New York Heart Association Functional Class I or II Heart Failure
    Henry J Dargie
    Department of Cardiology, Western Infirmary, Glasgow, Scotland
    J Am Coll Cardiol 49:1696-704. 2007
    ....
  69. ncbi request reprint Differences in arterial compliance, microvascular function and venous capacitance between patients with heart failure and either preserved or reduced left ventricular systolic function
    Sean Balmain
    British Heart Foundation Cardiovascular Research Centre, University of Glasgow, Glasgow G12 8TA, Scotland, UK
    Eur J Heart Fail 9:865-71. 2007
    ..These patients may have abnormalities of ventriculo-vascular coupling, due to increased vascular and ventricular stiffness...
  70. ncbi request reprint Epidemiology of heart failure and left ventricular systolic dysfunction after acute myocardial infarction: prevalence, clinical characteristics, and prognostic importance
    Robin A P Weir
    Department of Cardiology, Western Infirmary, Glasgow, United Kingdom, and Department of Medicine, Duke University Medical Center, Durham, NC, USA
    Am J Cardiol 97:13F-25F. 2006
    ..Given the high risks in this population, aggressive treatment, comprising early initiation and sustained use of evidence-based treatments, is essential for improving prognosis...
  71. doi request reprint Biomarkers in heart failure: a clinical review
    J Paul Rocchiccioli
    BHF Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, G12 8TA, Scotland, UK
    Heart Fail Rev 15:251-73. 2010
    ..This article reviews and summarises the most extensively investigated biomarkers currently available, with an emphasis on clinical applicability and discusses the future evaluation of candidate biomarkers in patients with heart failure...
  72. ncbi request reprint Angiotensin inhibition in heart failure
    John J V McMurray
    Department of Cardiology, Western Infirmary, Glasgow, G11 6NT, UK
    J Renin Angiotensin Aldosterone Syst 5:S17-22. 2004
    ..Candesartan had expected effects on blood pressure and renal function, emphasising the need for careful patient monitoring...
  73. doi request reprint Heart failure with preserved ejection fraction: clinical characteristics of 4133 patients enrolled in the I-PRESERVE trial
    John J V McMurray
    Department of Cardiology, Western Infirmary, Glasgow, and Faculty of Medicine, University of Glasgow, Scotland, UK
    Eur J Heart Fail 10:149-56. 2008
    ....
  74. doi request reprint Approaches to the treatment of anaemia in patients with chronic heart failure
    Clare L Murphy
    BHF Cardiovascular Research Centre, University of Glasgow, 126 University Place, Glasgow G12 8TA, Scotland, UK
    Heart Fail Rev 13:431-8. 2008
    ..Other approaches, notably parenteral iron supplementation, are also being evaluated and other agents for anaemia correction are under development...
  75. ncbi request reprint Effects of tezosentan on symptoms and clinical outcomes in patients with acute heart failure: the VERITAS randomized controlled trials
    John J V McMurray
    Department of Cardiology, Western Infirmary, Glasgow, G12 8QQ, United Kingdom
    JAMA 298:2009-19. 2007
    ..Tezosentan is an intravenous short-acting endothelin receptor antagonist that has favorable hemodynamic actions in heart failure...
  76. doi request reprint Lipid-modifying therapies and risk of pancreatitis: a meta-analysis
    David Preiss
    BHF Glasgow Cardiovascular Research Centre, University of Glasgow, 126 University Pl, Glasgow G12 8TA, United Kingdom
    JAMA 308:804-11. 2012
    ..Although lipid guidelines recommend fibrate therapy to reduce pancreatitis risk in persons with hypertriglyceridemia, fibrates may lead to the development of gallstones, a risk factor for pancreatitis...
  77. ncbi request reprint Heart failure
    John J V McMurray
    Department of Cardiology, Western Infirmary, Glasgow, UK
    Lancet 365:1877-89. 2005
    ..Many new pharmacological, device, and surgical treatments for heart failure are currently under evaluation in clinical trials, and other approaches, including stem-cell treatment, are at an earlier stage of investigation...
  78. ncbi request reprint What are the clinical consequences of anemia in patients with chronic heart failure?
    John J V McMurray
    Department of Cardiology, Western Infirmary, Glasgow, United Kingdom
    J Card Fail 10:S10-2. 2004
    ..Only intervention studies intended to correct anemia and evaluate the effect on clinical outcomes can verify these important hypotheses...
  79. doi request reprint Intensive glycemic control has no impact on the risk of heart failure in type 2 diabetic patients: evidence from a 37,229 patient meta-analysis
    Davide Castagno
    Cardiology Unit, Department of Internal Medicine, University of Turin, Italy
    Am Heart J 162:938-948.e2. 2011
    ..We conducted a meta-analysis of randomized controlled trials comparing strategies of more versus less intensive glucose-lowering that reported HF events...
  80. ncbi request reprint Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial
    John J V McMurray
    University of Glasgow, Glasgow, UK
    Lancet 362:767-71. 2003
    ..We aimed to find out whether these drugs improve clinical outcome...
  81. doi request reprint Pharmacist intervention in primary care to improve outcomes in patients with left ventricular systolic dysfunction
    Richard Lowrie
    Long Term Conditions and Research, Pharmacy and Prescribing Support Unit, NHS Greater Glasgow and Clyde, Queens Park House, Victoria Infirmary, Langside Road, Glasgow, UK
    Eur Heart J 33:314-24. 2012
    ..Meta-analysis of small trials suggests that pharmacist-led collaborative review and revision of medical treatment may improve outcomes in heart failure...
  82. ncbi request reprint Aspirin inhibits the acute arterial and venous vasodilator response to captopril in patients with chronic heart failure
    Iain M MacIntrye
    Division of Cardiovascular and Medical Sciences, University of Glasgow, UK
    Cardiovasc Drugs Ther 19:261-5. 2005
    ..We sought to determine the effects of low dose aspirin on the peripheral hemodynamic effects of captopril in patients with chronic heart failure (CHF)...
  83. ncbi request reprint A putative placebo comparison of the SCOPE and LIFE trials
    Peter A Meredith
    Division of Cardiovascular and Medical Sciences, University of Glasgow, Gardiner Institute, Western Infirmary, Scotland, UK
    J Renin Angiotensin Aldosterone Syst 5:59-63. 2004
    ..Neither trial is sufficiently 'powered' to demonstrate a benefit in CHD outcomes, but with SCOPE there was a trend towards benefit with a point estimate compatible with the major meta-analysis...
  84. ncbi request reprint Increase in serum adiponectin concentration in patients with heart failure and cachexia: relationship with leptin, other cytokines, and B-type natriuretic peptide
    Margaret B McEntegart
    BHF Cardiovascular Research Centre, University of Glasgow, Glasgow, Scotland, UK
    Eur Heart J 28:829-35. 2007
    ..Adiponectin concentration is inversely related to body weight and, in animals, causes weight loss. We, therefore, measured adiponectin concentration in patients with heart failure (HF) and cachexia...
  85. ncbi request reprint Chronic kidney disease in patients with cardiac disease: a review of evidence-based treatment
    John J V McMurray
    Department of Cardiology, Western Infirmary, Glasgow, Scotland, United Kingdom
    Kidney Int 68:1419-26. 2005
  86. ncbi request reprint Treatment of heart failure with spironolactone--trial and tribulations
    John J V McMurray
    Department of Cardiology, Western Infirmary, Glasgow, Scotland, United Kingdom
    N Engl J Med 351:526-8. 2004
  87. ncbi request reprint Heart failure in a cold climate. Seasonal variation in heart failure-related morbidity and mortality
    Simon Stewart
    Clinical Research Initiative in Heart Failure, University of Glasgow, Glasgow, Scotland, United Kingdom
    J Am Coll Cardiol 39:760-6. 2002
    ..This study was done to determine whether seasonal variation exists in hospitalizations and deaths due to heart failure (HF) and to examine possible contributors to such variability...